
POLICY DETERMINATION



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

***Current Policy Effective Date: 2/14/25**

Title: 90624 Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use

Brief Description of Service:

- **Meningitis Vaccines:**
 - **90624:** Meningococcal Pentavalent Vaccine, Serogroups A, C, W, Y Conjugate, Recombinant
 - Received FDA approval, February 15, 2025. It represents a critical step forward in preventing meningococcal disease, a potentially life-threatening condition.

Vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease and could reduce number of injections to simplify immunization, if approved

GSK's 5-in-1 MenABCWY vaccine candidate combines the antigenic components of its two well-established meningococcal vaccines with demonstrated efficacy and safety profiles, BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine). The MenABCWY combination will target the five groups of the bacteria *Neisseria meningitidis* (Men A, B, C, W, and Y) that cause most invasive meningococcal disease (IMD) cases globally.¹

Combining the protection offered by these vaccines into fewer shots aims to reduce the number of injections, simplifying immunization. This can help increase series completion and vaccination coverage and help reduce the overall burden of IMD, with unvaccinated adolescents being at particular risk of infection and potential outbreaks.^{2,3,4}

IMD is an unpredictable but serious illness that can cause life-threatening complications.⁵ Despite treatment, among those who contract IMD one in six will die, sometimes in as little as 24 hours.^{6,7} One in five survivors may suffer long-term consequences such as brain damage, amputations, hearing loss and nervous system problems.⁸ Although anyone can get

IMD, those who are in their late teens and early adulthood are amongst the groups at higher risk of contracting it.

The U.S. Food and Drug Administration February 14, 2025, Penmenvay (meningococcal groups A, B, C, W, and Y vaccine) is covered for its FDA approved indications.

The CPT code for this vaccine is effective 10/01/24

ACIP approved majority votes at its April 15-16, 2025, meeting

ACIP recommends GSK's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit.

Recommendation:

The Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use vaccine is **established**.

CPT/HCPCS Level II Codes (Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)

Established codes:

90624

Other codes (investigational, not medically necessary, etc.):

NA

References:

1. CDC. *Meningococcal Disease Causes and How It Spreads*. Available at: <https://www.cdc.gov/meningococcal/about/causes-transmission.html> accessed 2/9/26
2. Bekkat-Berkani R, Fragapane E, Preiss S, Rappuoli R et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB, *Journal of Infection* Vol 85, Issue 5, p481-491, published November 2022.
3. Huang L, Snedecor S et al. Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States, *Postgraduate Medicine*, 134(4):341-348 published May 2022.
4. CDC. *University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018* - Volume 25, Number 3—March 2019 - *Emerging Infectious*

- Diseases journal - CDC. Available at: https://wwwnc.cdc.gov/eid/article/25/3/18-1574_article. Accessed 2/9/26
5. CDC. *Bacterial Meningitis*, Available at: [About Bacterial Meningitis | Meningitis | CDC](#) Accessed 2/9/26
 6. World Health Organization. *Meningitis fact sheet*. Available at: [Meningitis](#) accessed 2/9/26
 7. Thompson MJ et al. Clinical recognition of meningococcal disease in children and adolescents. *Lancet*. 2006. 367, 397-403.
 8. Vaccines Licensed for the Use in the United States [Vaccines Licensed for Use in the United States | FDA](#) accessed 2/9/26
 9. New CPT Codes Release: Essential Updates for 2024-2025 Vaccine Administration [New CPT Codes Released: Essential Updates for 2024-2025 Vaccine Administration](#) accessed 2/9/26
 10. GSK Update [GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices - BioSpace](#)
[CDC advisers update recommendations for meningococcal, RSV, chikungunya vaccines | CIDRAP](#)
accessed 2/9/26
 11. Advisory Committee on Immunization Practices (ACIP) [ACIP Recommendations | ACIP | CDC](#) accessed 2/9/26

Joint Blue Cross/BCN Medical Policy History

Policy Effective Date	Blue Cross Signature Date	BCN Signature Date	Comments
7/1/25	4/21/25		Policy determination – EI (jf) Vendor Managed: N/A
2/14/25	4/21/26		Policy determination – EST (jf) Vendor Managed: N/A

Next Review Date: This is an established policy and no longer subject to periodic review